TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33113552
Drug: Nivolumab (anti-PD1)
Normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (anti-PD1) first-line therapy
Study: 32917317
Drug: PPE 400
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PPE 400 mg per day
Study: 36094202
Drug: Ensitrelvir 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensitrelvir 20, 70, 250, 500, 1,000, or 2,000 mg (part 1)
Study: 36094202
Drug: Ensitrelvir 375/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensitrelvir 375/125 mg or 750/250 mg once daily for 5 days (part 2)
Study: 36094202
Drug: Ensitrelvir 750/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensitrelvir 750/250 mg coadministered with midazolam
Study: 35166054
Drug: SAR342434 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR342434 insulin lispro
Study: 35166054
Drug: Humalog insulin
Normalized name: insulin lispro Cartridge [Humalog]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humalog insulin lispro
Study: 33518076
Drug: Conventional cages
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cages (CC)
Study: 33894327
Drug: Golexanolone (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golexanolone (10, 40 or 80 mg BID)
Study: 33079152
Drug: 15-mg/d vericiguat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg/d vericiguat
Study: 33079152
Drug: 10-mg/d vericiguat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg/d vericiguat
Study: 34653328
Drug: Liquid L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid L-thyroxine (T4® drops)
Study: 34653328
Drug: Tablets L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets L-thyroxine (T4® tablets)
Study: 32736555
Drug: Experiential Learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential Learning (EL) intervention, which included a lively presentation on oral health and role play in a simulated dental clinic.
Study: 35078520
Drug: Pediatric Tuina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric Tuina plus conventional treatment
Study: 36114133
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (optimal nonpharmacologic therapy)
Study: 34557956
Drug: Sham PBM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham PBM therapy
Study: 32954647
Drug: Qishen Yiqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishen Yiqi dripping pills (QSYQ) for 6 months
Study: 33907224
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g tablet formulation
Study: 34488845
Drug: Low-cell dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-cell dose treatment group (n = 30)
Study: 34488845
Drug: High-cell dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-cell dose treatment group (n = 30)
Study: 35659571
Drug: Response-adjusted protocol
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response-adjusted protocol (n=27) with tapering doses of prednisone over 8 weeks
Study: 35659571
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group (n=32) with standard protocol (60 mg/m2/24 hours for 6 weeks, followed by 40 mg/m2/48 hours for 4 weeks, followed by a slow taper for a total of 24 weeks)
Study: 34273257
Drug: Whole tablets
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tablets of apalutamide
Study: 32103926
Drug: Budesonide/Glycopyrrolate/Formoterol Fumarate
Normalized name: budesonide/glycopyrrolate/formoterol fumarate 160 mcg-9 mcg-4.8 mcg/actuation INHALATION HFA AEROSOL WITH ADAPTER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/Glycopyrrolate/Formoterol Fumarate (BUD/GLY/FORM) triple therapy
Study: 32103926
Drug: Budesonide/Formoterol Fumarate
Normalized name: budesonide/formoterol fumarate 80/4.5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/Formoterol Fumarate (BUD/FORM) dual therapy
Study: 32103926
Drug: BUD/GLY/FORM triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/GLY/FORM triple therapy
Study: 32393320
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care including home exercise (UCHE) plus spa therapy (18 days of mud packs, underwater massages, showers and water exercises under medical supervision)
Study: 32393320
Drug: UCHE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCHE plus spa therapy
Study: 34785236
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg, once daily)
Study: 33242515
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to prescribed medications
Study: 32762226
Drug: Hemocoagulase treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemocoagulase treatment in patients with low coagulation index (CI)
Study: 32897569
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 1 g intravenous initially, then every 6 months for 12 months
Study: 32897569
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) 40 mg subcutaneously 3 times/week for 12 months
Study: 32410586
Drug: Perceived health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived health benefits of treatment for perinatal depression
Study: 32826784
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (2× weekly, 60-minute sessions for 12 weeks)
Study: 34657138
Drug: AGMG0201 (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGMG0201 (active study drug)
Study: 34657138
Drug: AGMG0201 (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGMG0201 (high-dose group)
Study: 34657138
Drug: AGMG0201 (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGMG0201 (low-dose group)
Study: 34062976
Drug: Aguamiel-based beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aguamiel-based beverage fermented with Lactobacillus plantarum, Lactobacillus paracasei and Lactobacillus brevis (100 mL, 3 × 10^8 cfu/mL) for 8 weeks
Study: 32381495
Drug: Video-observed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-observed therapy (VOT)
Study: 32362132
Drug: HiBalance intervention
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiBalance intervention (10-week, two times weekly progressive balance training led by physical therapists)
Study: 35623183
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled nitric oxide (iNO) at 250 ppm for 30 minutes
Study: 32854536
Drug: Sequential afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sequential afatinib followed by osimertinib
Study: 33995600
Drug: Apatinib 500
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg once daily
Study: 35184413
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of apatinib and melittin
Study: 35050320
Drug: Pembrolizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (2 mg/kg or 10 mg/kg every 2 or 3 weeks)
Study: 35368773
Drug: Tongdu Bushen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongdu Bushen acupuncture, intradermal acupuncture, and moxibustion integrated therapy combined with core muscle training program (CMT)
Study: 36177926
Drug: Xiaoqinglong Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoqinglong Decoction (1 000 mg/L)
Study: 36177926
Drug: Qingqi Huatan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingqi Huatan Pill (1 000 mg/L)
Study: 36177926
Drug: PDTC (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDTC (100 μmol/L)
Study: 33759250
Drug: Emodepside as
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emodepside as LSF, single oral administration of 20 mg
Study: 33759250
Drug: Emodepside as
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emodepside as LSF, multiple oral administration over 10 days at 5 mg once daily and 10 mg once daily and 10 mg twice daily
Study: 33759250
Drug: Emodepside as
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emodepside as IR tablet, 5 or 20 mg
Study: 33759250
Drug: Emodepside as
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emodepside as LSF, doses from 1 to 40 mg
Study: 32201234
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg every 2 weeks for up to 12 months)
Study: 32201234
Drug: Durvalumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab + Tremelimumab (12 weeks durvalumab 20 mg/kg + tremelimumab 1 mg/kg q4w then 34 weeks durvalumab 10 mg/kg q2w)
Study: 33289149
Drug: Postoperative decrease
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative decrease of albumin (ΔAlb) calculated on postoperative day 1, with a cut-off established at 11 g/L.
Study: 36344108
Drug: IVC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVC and lung ultrasound-guided decongestion therapy
Study: 36344108
Drug: Clinical-guided decongestion
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical-guided decongestion therapy
Study: 33928857
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid Injection (CI)
Study: 34637505
Drug: High-protein milk-cereal
Normalized name: milk protein concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein milk-cereal mix (5.6 g protein, PER: 18%, 1.68 g from milk source)
Study: 34637505
Drug: Modest-protein milk-cereal
Normalized name: milk protein concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modest-protein milk-cereal mix (2.5 g protein, PER: 8%; 0.75 g from milk source)
Study: 32390309
Drug: 5% Benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Benzoyl Peroxide (BPO), twice a day
Study: 32390309
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5% BPO + 3% Erythromycin, twice a day
Study: 32390309
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 4% Niacinamide + 1% Gallic Acid + 1% Lauric Acid, twice a day
Study: 36376310
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of CoronaVac at a 10-month interval (cohort 1)
Study: 36376310
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of CoronaVac at a 12-month interval (cohort 2)
Study: 35854358
Drug: 1-h music
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-h music listening sessions twice daily through noise-canceling headphones
Study: 35854358
Drug: 1-h sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-h sessions of a silence track twice daily through noise-canceling headphones
Study: 35483010
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by chemoradiotherapy (INCT‐CRT)
Study: 35483010
Drug: Chemoradiotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemoradiotherapy followed by consolidation chemotherapy (CRT‐CNCT)
Study: 34185584
Drug: Eplerenone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone treatment
Study: 35684021
Drug: RiaGev (Nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: RiaGev (Nicotinamide and D-Ribose) 1520 mg twice daily for 7 days
Study: 33620439
Drug: ≥50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥50% of the target β-blocker dose
Study: 33620439
Drug: <50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: <50% of the target β-blocker dose
Study: 32094049
Drug: Gentamicin implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin implant
Study: 33239152
Drug: Inhaled control
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled control medication (ICM)
Study: 33239152
Drug: Short-acting beta-agonists
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta-agonists (SABA)
Study: 33627253
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum MBL (≤100 μg/L)
Study: 32690640
Drug: rhu-pGSN single-dose
Normalized name: Rhu-pGSN
DrugBank: Recombinant human plasma gelsolin (DB15746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhu-pGSN single-dose at 6 mg/kg
Study: 32690640
Drug: rhu-pGSN multidose
Normalized name: Rhu-pGSN
DrugBank: Recombinant human plasma gelsolin (DB15746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhu-pGSN multidose at 6, 12, or 24 mg/kg for 3 consecutive days
Study: 32690640
Drug: Placebo single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single-dose
Study: 35839439
Drug: Combination cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cognitive behavioral therapy and medication management algorithm
Study: 35839439
Drug: Enhanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced standard of care (psychotherapy and medication management)
Study: 34510174
Drug: High-spice diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-spice diet (HSD) 6.6 g/d/2100 kcal
Study: 34510174
Drug: Moderate-spice diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-spice diet (MSD) 3.3 g/d/2100 kcal
Study: 34510174
Drug: Low-spice diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-spice diet (LSD) 0.5 g/d/2100 kcal
Study: 36075583
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy (RT) using digital material or storytelling for 4 weeks
Study: 32385554
Drug: 4% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% chlorhexidine solution (CHG)
Study: 34114501
Drug: Bioabsorbable bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable bone hemostatic agent (BBHA)
Study: 34015041
Drug: 2-day levofloxacin
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-day levofloxacin treatment
Study: 34015041
Drug: CRP-guided levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRP-guided levofloxacin treatment
Study: 33074327
Drug: Bimagrumab 700
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 700 mg monthly for 6 months
Study: 32872052
Drug: Conventional low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional low-dose spiral CT scan
Study: 35758442
Drug: Dual trigger
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual trigger using gonadotropin releasing hormone agonist with human chorionic gonadotropin (hCG)
Study: 34348576
Drug: Vagus nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus nerve stimulation (VNS) as an adjunct to anti-seizure medications (ASMs)
Study: 34348576
Drug: Anti-seizure medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-seizure medications (ASMs) only
Study: 36116461
Drug: V116-1 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: V116-1 (2 μg per pneumococcal polysaccharide [PnP] per 0·5 mL)
Study: 36116461
Drug: V116-2 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: V116-2 (4 μg per PnP per 1·0 mL)
Study: 36116461
Drug: PPSV23 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPSV23 (25 μg per PnP per 0·5 mL)
Study: 36116461
Drug: V116 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: V116 (4 μg per PnP per 1·0 mL)
Study: 34958620
Drug: Oxytocin plus
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin plus misoprostol (400 µg sublingual)
Study: 33350222
Drug: Flunarizine combined
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine combined with Tongtian Oral Liquid
Study: 33350222
Drug: Flunarizine combined
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine combined with Zhengtian Pills
Study: 33350222
Drug: Flunarizine combined
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine combined with Toutongning Capsules
Study: 33350222
Drug: Flunarizine combined
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine combined with Tianshu Capsules
Study: 33350222
Drug: Flunarizine combined
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine combined with Xuefu Zhuyu Capsules
Study: 33350222
Drug: Flunarizine combined
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine combined with Danzhen Toutong Capsules
Study: 33350222
Drug: Flunarizine combined
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine combined with Songling Xuemaikang Capsules
Study: 33350222
Drug: Flunarizine combined
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine combined with Yuntongding Capsules
Study: 33350222
Drug: Flunarizine combined
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine combined with Danqi Soft Capsules
Study: 35491963
Drug: Acetaminophen 1
Normalized name: acetaminophen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 g IV with morphine 0.1 mg/kg
Study: 35491963
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV with morphine 0.1 mg/kg
Study: 35589575
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg hepatitis B vaccine at 0-1-6 month
Study: 35589575
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg hepatitis B vaccine at 0-1-2-6 month
Study: 35589575
Drug: 60 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg hepatitis B vaccine at 0-1-2-6 month
Study: 35026342
Drug: Vunakizumab 40
Normalized name: Vunakizumab
DrugBank: Vunakizumab (DB15154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vunakizumab 40 mg
Study: 35026342
Drug: Vunakizumab 80
Normalized name: Vunakizumab
DrugBank: Vunakizumab (DB15154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vunakizumab 80 mg
Study: 35026342
Drug: Vunakizumab 160
Normalized name: Vunakizumab
DrugBank: Vunakizumab (DB15154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vunakizumab 160 mg
Study: 39332633
Drug: Vunakizumab 240
Normalized name: Vunakizumab
DrugBank: Vunakizumab (DB15154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vunakizumab 240 mg
Study: 34216635
Drug: Non-pharmaceutical interventions
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmaceutical interventions (NPIs) implemented during the Covid-19 pandemic
Study: 32465366
Drug: Point of
Normalized name: Precision Point of Care Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point of Care (POC) management of coagulopathy using ROTEM, PFA 200, Multiplate, and 5% albumin solution
Study: 35435961
Drug: DEC-C (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC-C (35 mg decitabine and 100 mg cedazuridine)
Study: 35435961
Drug: IV decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV decitabine (20 mg/m2 once daily for the first 5 days of each 28-day cycle)
Study: 35228493
Drug: Textured Soybean
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textured Soybean Protein (40 g in 2 dishes for 4 weeks)
Study: 32811427
Drug: High-dose rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rabeprazole (20 mg twice daily)
Study: 32811427
Drug: Standard-dose rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose rabeprazole (20 mg once daily)
Study: 34487151
Drug: Pradefovir 45
Normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradefovir 45 mg
Study: 34016045
Drug: Remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam besylate (Group R) - induction dose of 0.2 mg/kg and maintenance dosage of 1.0 mg/kg/h
Study: 34016045
Drug: Propofol (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (Group P) - induction dose of 1.5–2.0 mg/kg and maintenance dosage of 3.0–6.0 mg/kg/h
Study: 32386275
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of tomato juice
Study: 32386275
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of tomato juice
Study: 35437951
Drug: Almonertinib (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonertinib (110 mg) under fasting conditions
Study: 35437951
Drug: Almonertinib (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonertinib (110 mg) under fed conditions
Study: 33012643
Drug: Generic drug
Normalized name: CELECOXIB 200 mg ORAL CAPSULE [Generic drug]
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic drug approval process video
Study: 34344706
Drug: OKZ 64
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKZ 64 mg every 2 weeks